ArticleEndocrine connections2025
Relationship between Meteorin-like protein and type 2 diabetes mellitus: an update and meta-analysis.
Article in Endocrine connections, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Metrnl in diabetes and its complications: divergent evidence and translational prospects.Journal of translational medicine · 2026Review
- Umbilical cord asprosin and subfatin levels in relation to neonatal metabolic outcomes in gestational diabetes mellitus: a cross-sectional study.BMC endocrine disorders · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Meteorin-like protein (Metrnl) is considered a novel adipokine, which plays an important role in the occurrence and development of type 2 diabetes mellitus (T2DM). In a previous meta-analysis, no significant difference in circulating Metrnl levels was found between T2DM patients and normal glucose tolerance individuals. However, these meta-analyses included limited studies, and more studies about Metrnl and T2DM were published recently. Therefore, the association between Metrnl and T2DM remains uncertain. Aim: This study aimed to systematically and comprehensively update the relationship between circulating Metrnl levels and T2DM. Methods: A systematic search was conducted on the Web of Science, Wiley Online Library, PubMed, and Ovid databases using the terms 'type 2 diabetes mellitus' in combination with 'Metrnl'. Meta-analysis results were reported as standardized mean differences (SMDs) with corresponding 95% confidence intervals (CIs). Results: In total, 17 studies, including 649 patients with T2DM and 396 healthy controls, were included in the meta-analysis. We found that circulating Metrnl levels were lower in patients with T2DM than in healthy individuals (SMD: -0.47, 95% CI: (-0.98, 0.05); prediction interval: (-3.66, 2.73)). Moreover, serum Metrnl levels in patients with T2DM were significantly lower than in healthy individuals (SMD: -0.91, 95% CI: (-1.60, -0.22); prediction interval: (-5.03, 3.21)). Conclusions: This study aimed to systematically and comprehensively update the relationship between circulating Metrnl levels and T2DM. A clearer understanding of the role of Metrnl in T2DM could facilitate the development of effective treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.